Rightway
A pharmacy benefit manager for employers that passes drug rebates through and charges a flat fee, pairing it with pharmacist and nurse guidance. Just raised $155M; reported valued at $1.75B.
Rightway, Sep 24, 2026; Briefs Finance, Sep 24, 2026- Valuation
- $1.75B, reported after the Sep 2026 Series E, per an unnamed source; up from $1.1B in 2021.
- Raised
- About $392M sum of five announced rounds, 2019 to 2026. One report says $281M; the figures conflict.
- Clients
- 45 Fortune 500 employers among its clients, including Tyson Foods, won from CVS Caremark in 2024.
- Watch
- PBM reform a Feb 2026 law requires 100% rebate pass-through to employer plans from 2029, which Rightway already offers.
- AI
- Backend only the Series E is partly for AI; no public API, MCP server or llms.txt found.
- Liquidity
- No tender reported but the 2026 Form D lists $22.7M of proceeds going to officers, directors or promoters.
- Hiring
- 28 → 25 remote listings since Oct 10.
A flat admin fee, not a cut of drug spend.
Rightway runs pharmacy benefits for self-funded employers and sells care navigation. Under its SureSpend model it earns an administration fee rather than revenue from drugs dispensed, passes 100% of rebates to the plan, owns no pharmacies, and refunds every dollar of spend above a set monthly cost, with no cap. It does not publish fees or revenue.
Rightway, Jan 21, 2026- 1A model the big three are being pushed towardRightway already passes all rebates through and owns no pharmacies. Congress and FTC settlements are now pushing CVS Caremark and Express Scripts toward similar options.Rightway, Jan 2026; AJMC, Jul 2026
- 2Pharmacists and nurses inside the benefitRemote clinical pharmacists act as a 'pharmacist in the family', and nurses handle triage and navigation, which most fee-only PBMs do not bundle.Rightway job posting, checked Nov 3, 2026
- 3Proof it can run very large plansTyson Foods, with about $200M of pharmacy spend and 140,000 staff, moved from CVS Caremark in 2024. Rightway now counts 45 Fortune 500 clients.CNBC, Jan 24, 2024; Rightway, Sep 2026
- Judi Health (formerly Capital Rx)$3.25Bprivate, Sep 23
- Rightway$1.75BSeries E, Sep 24
Private values are the last reported round; they can be stale. Listed values are market value. Bars start at zero.
Every round, and what its terms give away.
Rightway is private, so there is no share price. What its investors paid, and on what terms, is the closest thing to one.
- $1.75B
- latest valuation, Series E Sep 24
- $392M
- raised in all
Reported as profitable (Briefs Finance, Sep 2026). Revenue grew 2,824% from FY2021 to FY2024, per Deloitte Fast 500; no dollar figure.
Rightway, Nov 19, 2025; Briefs Finance, Sep 2026Post-money valuations as reported. The line starts at zero. Rounds without a reported valuation are left off.
- Sep 24Series E$155M at $1.75BLed by Francisco Partners. About 9% of the company, if all new sharesThrive and Khosla joined. Valuation reported by an unnamed source. The Form D lists 6 investors and estimates $22.7M paid to officers, directors or promoters.Rightway, Sep 24, 2026; SEC Form D; Briefs Finance
- Mar 25Series D$109MLed by Not disclosedKnown only from a Form D: $108,749,915 sold to 14 investors. No announcement found.SEC Form D, filed Mar 29, 2024
- Mar 30Series C$100M at $1.10BLed by Khosla Ventures. About 9% of the company, if all new sharesThrive Capital and Tiger Global joined. Launched its own PBM around this time.Rightway, Mar 30, 2021
- Nov 15Series B$20MLed by Thrive CapitalTo expand into pharmacy benefits. Form D shows $19.25M sold to 6 investors.Built In NYC, Nov 22, 2019; SEC Form D
- Feb 28Series A$8.0MLed by Not namedFamily offices; Jonathan Locker, formerly of Tiger Global, joined the board.Rightway, Feb 28, 2019
- Down round or flat round?No sign of one. The reported $1.75B Series E value is about 59% above the $1.1B Series C. The 2024 Series D value was never disclosed.Briefs Finance, Sep 2026; Rightway, Mar 2021Clear
- How much of the company the last round soldAbout 9%: $155M at a reported $1.75B, if that figure is post-money. Reports do not say.Briefs Finance, Sep 24, 2026Clear
- Time since the last raiseAbout six weeks; the Form D shows a first sale on Aug 25, 2026. The company is reported to be profitable.SEC Form D, filed Sep 8, 2026Clear
- Who led the last roundFrancisco Partners, a new outside lead. Existing backers Thrive Capital and Khosla Ventures followed.Rightway, Sep 24, 2026Clear
- Who got the moneyThe 2026 Form D estimates $22,671,053 of proceeds paid to officers, directors or promoters (2024: $2,499,995). This often means insiders sold shares; the filing does not say.SEC Form D, filed Sep 8, 2026Flag
- Tender offers or secondary sales for staffNo staff tender offer found in company news or press. Whether rank-and-file holders could sell in 2026 is not known.Rightway press page, checked Nov 3, 2026Open
- Layoffs in the last 12 monthsNo layoff found in news searches or company posts. 33 roles were open on Nov 3, 2026.Greenhouse board, checked Nov 3, 2026Open
Clear: checked, nothing found. Flag: found, with the source. Open: could not be checked.
No filing reported; reported to be weighing an IPO within about four years
The rest of Rightway, for members.
The fine print, who gets paid most, where it looks headed and our calls. Free for 3 days, then $9 a month.
- 03
What the record says, and what we think it means.
10 flags, each with our read
- 04
Sales is paid 17% under market. Clinical, 70% under.
Posted pay against the market, 2 teams
- 05 · 06
How Rightway uses AI, and what its hiring says.
- 07
What Rightway could be worth, three ways.
- 08
The signals, and which way they push.
4 signals
- 09
Where Rightway ends up, if we had to bet.
5 predictions, with odds
Read by the Still Remote research agent on November 4, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.